Application of Liposomal Technologies for Delivery of Platinum Analogs in Oncology

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2013 Sep 12

PMID 24023517

Citations 29

Authors

Demin Liu

Chunbai He

Andrew Z Wang

Wenbin Lin

Affiliations

Soon will be listed here.

Abstract

Platinum-based chemotherapy, such as cisplatin, oxaliplatin, and carboplatin, is one of the most widely utilized classes of cancer therapeutics. While highly effective, the clinical applications of platinum-based drugs are limited by their toxicity profiles as well as suboptimal pharmacokinetic properties. Therefore, one of the key research areas in oncology has been to develop novel platinum analog drugs and engineer new platinum drug formulations to improve the therapeutic ratio further. Such efforts have led to the development of platinum analogs including nedaplatin, heptaplatin, and lobaplatin. Moreover, reformulating platinum drugs using liposomes has resulted in the development of L-NDPP (Aroplatin™), SPI-77, Lipoplatin™, Lipoxal™, and LiPlaCis®. Liposomes possess several attractive biological activities, including biocompatibility, high drug loading, and improved pharmacokinetics, that are well suited for platinum drug delivery. In this review, we discuss the various platinum drugs and their delivery using liposome-based drug delivery vehicles. We compare and contrast the different liposome platforms as well as speculate on the future of platinum drug delivery research.

Citing Articles

Stimuli-responsive nanocarrier delivery systems for Pt-based antitumor complexes: a review.

Wang T, Wu C, Hu Y, Zhang Y, Ma J RSC Adv. 2023; 13(24):16488-16511.

PMID: 37274408 PMC: 10233443. DOI: 10.1039/d3ra00866e.

Cisplatin-Loaded Thermosensitive Liposomes Functionalized with Hyaluronic Acid: Cytotoxicity and In Vivo Acute Toxicity Evaluation.

Gomes I, Silva J, Cassali G, de Barros A, Leite E Pharmaceutics. 2023; 15(2).

PMID: 36839905 PMC: 9961010. DOI: 10.3390/pharmaceutics15020583.

Sustained Drug Release from Smart Nanoparticles in Cancer Therapy: A Comprehensive Review.

Bai X, Smith Z, Wang Y, Butterworth S, Tirella A Micromachines (Basel). 2022; 13(10).

PMID: 36295976 PMC: 9611581. DOI: 10.3390/mi13101623.

Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy.

Buyana B, Naki T, Alven S, Aderibigbe B Int J Mol Sci. 2022; 23(19).

PMID: 36232561 PMC: 9569963. DOI: 10.3390/ijms231911261.

TRIP13 Induces Nedaplatin Resistance in Esophageal Squamous Cell Carcinoma by Enhancing Repair of DNA Damage and Inhibiting Apoptosis.

Zhang L, Ke L, Wu X, Tian H, Deng H, Xu L Biomed Res Int. 2022; 2022:7295458.

PMID: 35601150 PMC: 9115607. DOI: 10.1155/2022/7295458.

References

Bandak S, Goren D, Horowitz A, Tzemach D, Gabizon A . Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs. 2000; 10(10):911-20. DOI: 10.1097/00001813-199911000-00007. View

Meerum Terwogt J, Groenewegen G, Pluim D, Maliepaard M, Tibben M, Huisman A . Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol. 2002; 49(3):201-10. DOI: 10.1007/s002800100371. View

Zamboni W, Gervais A, Egorin M, Schellens J, Zuhowski E, Pluim D . Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol. 2003; 53(4):329-36. DOI: 10.1007/s00280-003-0719-4. View

Perez-Soler R, Lopez-Berestein G, Lautersztain J, Francis K, Raber M, Khokhar A . Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Cancer Res. 1990; 50(14):4254-9. View

Perez-Soler R, Lautersztain J, Stephens L, Wright K, Khokhar A . Preclinical toxicity and pharmacology of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Cancer Chemother Pharmacol. 1989; 24(1):1-8. DOI: 10.1007/BF00254097. View

Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo S, Zarghami N, Hanifehpour Y . Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013; 8(1):102. PMC: 3599573. DOI: 10.1186/1556-276X-8-102. View

White S, Lorigan P, Margison G, Margison J, Martin F, Thatcher N . Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer. 2006; 95(7):822-8. PMC: 2360546. DOI: 10.1038/sj.bjc.6603345. View

Smith B, Lyakhov I, Loomis K, Needle D, Baxa U, Yavlovich A . Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). J Control Release. 2011; 153(2):187-94. PMC: 3136211. DOI: 10.1016/j.jconrel.2011.04.005. View

Lopes de Menezes D, Pilarski L, Allen T . In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 1998; 58(15):3320-30. View

10.

Stathopoulos G, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K, Michalopoulou P . Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother Pharmacol. 2011; 68(4):945-50. PMC: 3180559. DOI: 10.1007/s00280-011-1572-5. View

11.

Gregoriadis G, Wills E, Swain C, TAVILL A . Drug-carrier potential of liposomes in cancer chemotherapy. Lancet. 1974; 1(7870):1313-6. DOI: 10.1016/s0140-6736(74)90682-5. View

12.

Klibanov A, Maruyama K, Torchilin V, Huang L . Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990; 268(1):235-7. DOI: 10.1016/0014-5793(90)81016-h. View

13.

Stathopoulos G, Boulikas T, Kourvetaris A, Stathopoulos J . Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. Anticancer Res. 2006; 26(2B):1489-93. View

14.

Bangham A, Standish M, Watkins J . Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965; 13(1):238-52. DOI: 10.1016/s0022-2836(65)80093-6. View

15.

Barabas K, Milner R, Lurie D, Adin C . Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol. 2009; 6(1):1-18. DOI: 10.1111/j.1476-5829.2007.00142.x. View

16.

Mayer L, Tai L, Bally M, Mitilenes G, GINSBERG R, Cullis P . Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta. 1990; 1025(2):143-51. DOI: 10.1016/0005-2736(90)90091-2. View

17.

Banerjee G, Nandi G, Mahato S, Pakrashi A, Basu M . Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J Antimicrob Chemother. 1996; 38(1):145-50. DOI: 10.1093/jac/38.1.145. View

18.

Allen T, Mehra T, Hansen C, Chin Y . Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1992; 52(9):2431-9. View

19.

Davidsen J, Jorgensen K, Andresen T, Mouritsen O . Secreted phospholipase A(2) as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue. Biochim Biophys Acta. 2003; 1609(1):95-101. DOI: 10.1016/s0005-2736(02)00659-4. View

20.

Boulikas T . Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs. 2009; 18(8):1197-218. DOI: 10.1517/13543780903114168. View